Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Study of Leniolisib in Pediatric APDS (4–11 Years) with Long-term Extension
jRCT2031220625Active, not recruiting
- Sponsor
- Pharming Group
- Start
- Jul 2023
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of leniolisib in Activated PI3Kδ syndrome (APDS), sponsored by Pharming Group. Primary endpoints: Part I: Safety - treatment-emergent adverse events, Part I: Safety - clinical laboratory changes and 8 more. Started Jul 2023; status: active, not recruiting.
02
Drugs
leniolisib
03
Conditions
Activated PI3Kδ syndrome (APDS)
Beyond the preview
Go deeper on jRCT2031220625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220625.